MedPath

Malaria study - bulaquine versus primaquine

Not Applicable
Completed
Conditions
Infections and Infestations
ncomplicated P. falciparum malaria
Uncomplicated P. falciparum malaria
Registration Number
ISRCTN50134587
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
93
Inclusion Criteria

1. Aged more than 16 years
2. Uncomplicated Plasmodium falciparum malaria
3. Gametocyte count more than 55 /ul within 72 hours of diagnosis, irrespective of asexual parasitemia
4. Willing to give written, informed consent

Exclusion Criteria

1. Pregnancy
2. Lactation
3. Allergy to primaquine or bulaquine
4. Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
5. Co-infection with Plasmodium vivax

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Gametocytemia at days 8, 15, 22 and 29 of follow-up
Secondary Outcome Measures
NameTimeMethod
Gametocyte viability at days 8, 15, 22 and 29
© Copyright 2025. All Rights Reserved by MedPath